Antiangiogenic peptide agents
AssigneeThe Regents of the University of California
InventorsRichard I. Weiner, Joseph A. Martial, Ingrid Struman, Robert Taylor, Frauke Bentzien
Life of this patent
Estimating the term…
Abstract
The current invention provides novel antiangiogenic peptides which correspond to about 133 consecutive amino acids of the N-terminal sequence of growth hormone.
Claims7
An isolated peptide having the amino acid sequence of SEQ ID NO:
- 24.
A method of treating an angiogenic disease in a subject, the method comprising administering to a subject in need of such treatment an angiogenesis inhibitory effective amount of an isolated peptide that has the amino acid sequence of SEQ ID NO:24.
A method of inhibiting tumor formation or growth in a patient, the method comprising administering to the patient an angiogenesis inhibitory effective amount of an isolated peptide that has the amino acid sequence of SEQ ID NO:24.
A pharmaceutical formulation, comprising:
- a pharmaceutically acceptable carrier;
- and
- a therapeutically effective amount of an isolated peptide that has the amino acid sequence of SEQ ID NO:24.
Dependencies are inferred from the claim text.